Press release
Graft vs Host Disease Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corporation
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graft vs Host Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Graft vs Host Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Graft vs Host Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graft vs Host Disease Market.
The Graft vs Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Graft vs Host Disease Pipeline Report: https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Graft vs Host Disease treatment therapies with a considerable amount of success over the years.
• Graft vs Host Disease companies working in the treatment market are Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others, are developing therapies for the Graft vs Host Disease treatment
• Emerging Graft vs Host Disease therapies in the different phases of clinical trials are- ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others are expected to have a significant impact on the Graft vs Host Disease market in the coming years.
• In September 2024, ReAlta Life Sciences, a US-based biopharmaceutical company, has administered the first dose in its Phase II clinical trial of RLS-0071 for the treatment of steroid-refractory acute graft-versus-host disease (aGvHD). This open-label, dose-escalation study aims to evaluate the tolerability, safety, pharmacokinetics, pharmacodynamics, dosing, and efficacy of RLS-0071 as a secondary treatment for aGvHD in patients unresponsive to steroid therapy. Participants will receive RLS-0071 for seven or 14 days, either alone or in combination with the standard treatment, ruxolitinib.
• In July 2024, Tr1X has administered the first dose to a patient in the TRX103-01 clinical trial, which is evaluating TRX103, a Type 1 Treg (Tr1) cell therapy for preventing Graft-versus-Host Disease (GvHD). The trial aims to assess the safety, pharmacokinetics, and pharmacodynamics of TRX103 in patients with hematologic malignancies undergoing mismatched hematopoietic stem cell transplantation (HSCT), focusing on GvHD prevention.
Graft vs Host Disease Overview
Graft-versus-host disease (GVHD) is a condition that occurs after a stem cell or bone marrow transplant, where the transplanted immune cells (graft) attack the recipient's body (host). This happens when the donor's immune cells recognize the recipient's tissues as foreign. GVHD can affect various organs, including the skin, liver, and gastrointestinal tract, and can cause symptoms such as rashes, jaundice, diarrhea, and abdominal pain. GVHD is a major complication of bone marrow transplants and can range from mild to severe. It is treated with medications to suppress the immune system.
Get a Free Sample PDF Report to know more about Graft vs Host Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Graft vs Host Disease Drugs Under Different Phases of Clinical Development Include:
• ABSK021: Abbisko Therapeutics
• SYN-004: Theriva Biologics
• SER-155: Seres Therapeutics
• CB103: Cellestia Biotech
• Glasdegib: Pfizer
• TQ 05105: Chia Tai Tianqing Pharmaceutical
• RGI-2001: Regimmune Corporation
• Axatilimab: Syndax Pharmaceuticals
• MaaT013: MaaT Pharma
• MC 0518: Medac
• Itolizumab: Equillium
• Elranatamab: Pfizer
• Felzartamab: Janssen Pharmaceutical
• T-Guard: Xenikos
• MaaT013: MaaT Pharma
• Axatilimab: Syndax Pharmaceuticals
• TQ 05105: Chia Tai Tianqing Pharmaceutical Group
Graft vs Host Disease Route of Administration
Graft vs Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
Graft vs Host Disease Molecule Type
Graft vs Host Disease Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
Graft vs Host Disease Pipeline Therapeutics Assessment
• Graft vs Host Disease Assessment by Product Type
• Graft vs Host Disease By Stage and Product Type
• Graft vs Host Disease Assessment by Route of Administration
• Graft vs Host Disease By Stage and Route of Administration
• Graft vs Host Disease Assessment by Molecule Type
• Graft vs Host Disease by Stage and Molecule Type
DelveInsight's Graft vs Host Disease Report covers around 65+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Graft vs Host Disease product details are provided in the report. Download the Graft vs Host Disease pipeline report to learn more about the emerging Graft vs Host Disease therapies
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Graft vs Host Disease Therapeutics Market include:
Key companies developing therapies for Graft vs Host Disease are - Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology, AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others.
Graft vs Host Disease Pipeline Analysis:
The Graft vs Host Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Graft vs Host Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft vs Host Disease Treatment.
• Graft vs Host Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Graft vs Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft vs Host Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Graft vs Host Disease drugs and therapies
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Graft vs Host Disease Pipeline Market Drivers
• Increase in the number of patients suffering from chronic GvHD, robust Pipeline of GvHD are some of the important factors that are fueling the Graft vs Host Disease Market.
Graft vs Host Disease Pipeline Market Barriers
• However, high cost of treatment, recognizing the limitations of currently available aGVHD therapies and other factors are creating obstacles in the Graft vs Host Disease Market growth.
Scope of Graft vs Host Disease Pipeline Drug Insight
• Coverage: Global
• Key Graft vs Host Disease Companies: Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others
• Key Graft vs Host Disease Therapies: ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others
• Graft vs Host Disease Therapeutic Assessment: Graft vs Host Disease current marketed and Graft vs Host Disease emerging therapies
• Graft vs Host Disease Market Dynamics: Graft vs Host Disease market drivers and Graft vs Host Disease market barriers
Request for Sample PDF Report for Graft vs Host Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Graft vs Host Disease Report Introduction
2. Graft vs Host Disease Executive Summary
3. Graft vs Host Disease Overview
4. Graft vs Host Disease- Analytical Perspective In-depth Commercial Assessment
5. Graft vs Host Disease Pipeline Therapeutics
6. Graft vs Host Disease Late Stage Products (Phase II/III)
7. Graft vs Host Disease Mid Stage Products (Phase II)
8. Graft vs Host Disease Early Stage Products (Phase I)
9. Graft vs Host Disease Preclinical Stage Products
10. Graft vs Host Disease Therapeutics Assessment
11. Graft vs Host Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Graft vs Host Disease Key Companies
14. Graft vs Host Disease Key Products
15. Graft vs Host Disease Unmet Needs
16 . Graft vs Host Disease Market Drivers and Barriers
17. Graft vs Host Disease Future Perspectives and Conclusion
18. Graft vs Host Disease Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Graft vs Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Graft vs Host Disease-Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Graft vs Host Disease Epidemiology https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Graft vs Host Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft vs Host Disease Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corporation here
News-ID: 3877232 • Views: …
More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…

Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…

Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…

Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Graft
Bone Graft and Graft Substitute Market Latest Research, Top Impacting Factors, G …
The "Bone Graft and Graft Substitute Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. A bone graft is a surgical treatment used to repair problems with bones or joints. Bone grafting, or transplanting of bone tissue, is useful in fixing bones that are impaired from trauma or problem joints. Bone growth around an embedded…
Synthetic Bioactive Bone Graft Substitutes Market Growing need for bone graft su …
Global Synthetic Bioactive Bone Graft Substitutes Market Overview:
The Synthetic Bioactive Bone Graft Substitutes market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Synthetic Bioactive Bone Graft Substitutes market has experienced significant growth, driven by factors such as increasing consumer demand,…
Bone Graft Substitutes Market Size to Hit $3.8 Billion by 2028 | Bone Graft Subs …
Market Overview:
According to our experience research team, Bone Graft Substitutes Market was valued at USD 2.7 Billion in 2021, and the global Bone Graft Substitutes industry is projected to reach a value of USD 3.8 Billion by 2028, at a CAGR of 5.9% during the forecast period 2022-2028
Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology,…
Graft Delivery Devices Market Facts, Figures and Analytical Insights, 2017 to 20 …
Global Graft Delivery Devices Market: Snapshot
Graft delivery relates to the surgically transplantation of a piece of living tissues and the procedure can be highly essential as well as complex at the same time. Consequently, technological advancements have paved way to graft delivery devices that can minimally breach bone, fat, and vascular parts of the body to transfer drugs during plastic and reconstructive surgeries as well as arthroscopic and orthopedic surgeries.…
Glass Graft Polyols Market 2019| BASF SE, Sinopec, Shell, Oltchim, The Dow Chemi …
Market Research Hub (MRH) has actively included a new research study titled “Global Graft Polyols Market” Research Report 2019 to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until forecast period limit; 2025. In…
Global Vascular Graft Market Growth Analysis Report 2018-2025Global Vascular Gra …
Research Report 2018-2025 on "Global Vascular Graft Market" which provides an outlook of current market value of Vascular Graft Market as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% in Vascular Graft Market by the end of 2025. The report on the global Vascular Graft market uses the top-down and bottom-up approaches to define, analyze, and describe the Vascular Graft market 2018 trends…